The NHS Innovation and Technology Payment (ITP) 2019/20 programme went live on 1 April 2019 and aims to remove barriers to the spread and adoption of innovative products or technologies (medical devices, digital platforms), including financial negotiations.
The innovations supported through the ITP 2019/20 are:
This innovation aims to reduce the side effects for men undergoing radiation treatment for prostate cancer. SpaceOAR is a gel which is injected into the space between the prostate and rectum to increase the space between these two organs by around 1cm. Creating this space makes it less likely that the rectum is exposed to radiation during cancer treatment. Read more here.
This is a handheld, patient-controlled, non-invasive vagus nerve stimulator. It is used for preventing and treating cluster headaches. Read more here.
Placental growth factor (PIGF) based testing
PlGF-based testing can be used with clinical judgement and other diagnostic tests to help diagnose suspected pre-eclampsia. Pre-eclampsia is a condition that affects some pregnant women, usually during the second half of pregnancy. It causes high blood pressure and protein in the urine and, if not diagnosed and closely monitored, it can lead to potentially life-threatening complications. Read more here.
High-sensitivity troponin testing
High sensitivity troponin assays have been developed to detect lower levels of troponin in the blood earlier than older standard assays, leading to improved early detection of acute heart attacks. Read more here
The AHSN Network will continue to support the ITP 2018/2019 scheme:
Available until March 2020
- Endocuff Vision® - a new type of bowel scope that improves colorectal examination for patients undergoing bowel cancer screening. For every 1000 patients treated it is estimated that 6 cases of cancer could be avoided through the use of this device. Read more.
- Heartflow® - advanced image analysis software that creates a 3D model of the coronary arteries and analyses the impact that blockages have on blood flow to rapidly diagnose patients with suspected Coronary Heart Disease (CAD). Its use may avoid the need for invasive investigations and provide a cost saving of £214 per patient. Recommended by NICE. Read more.
- Ethicon Plus Antibacterial Sutures - a new type of surgical suture that reduces the rate of Surgical Site Infection (SSI), such as MRSA, through the use of antimicrobial suture packs. Read more.
- SecurAcath - a device to secure catheters that is associated with a low incidence of catheter-associated complications, improved stability and reduced infection risk for patients with a peripherally inserted central catheter. The device has the potential for cost savings from a reduction in the time taken during dressing changes. Recommended by NICE. Read more.
The AHSN Network will continue to support the Innovation and Technology Tariff (ITT) 2017/18
The innovation to be reimbursed based on the number of uses is:
The innovation provided at the same cost as current procedures is:
- Urolift (ITT)
An alternative surgical procedure that can be performed as a day case for benign prostatic hyperplasia (BPH), a common and chronic condition where the enlarged prostate can make it difficult for a man to pass urine. Read more.
Faecal Microbiota Transplantation (FMT)
FMT is used to treat C-Diff infection as a third line treatment (5% patients). First and second line treatment is antibiotics. Cure rate is 90%. Read more and download a one-slide PowerPoint.
The central funding mechanism for all products on the ITT/ITP programme will end on 31st March 2021, with qualifying technologies transitioning over to the MedTech Funding Mandate
, published in January 2021. For 2021/22 it comprises 4 technologies, placental growth factor based testing (PlGF), SecurAcath, HeartFlow FFRCT and gammaCore.
Further technologies will be added annually. Some of the technologies in Year 1 have already been already adopted by trusts across England, including Wessex. Wessex AHSN can support both providers and commissioners with policy interpretation, implementation and transition from ITP to the MTFM. Details of AHSN support available is specifically referenced in the Guidance (paragraph 64 and 86 onwards).
All other ITT/ITP Programme products and technologies will no longer be funded. Technologies that are no longer recognised by the MedTech Funding Guidance will require a local decision to take over funding. Sites interested in continued adoption will need to explore and follow their local organisational processes (eg create a business case).
For more information please refer to our briefing document or get in touch with the team directly.